Initiation of antiretroviral therapy during acute HIV-1 infection leads to a high rate of nonreactive HIV serology

Clinical Infectious Diseases

Volumn 63, Issue 4, 2016, Pages 555-561

  De Souza, Mark S ^a,b   Pinyakorn, Suteeraporn ^c,d   Akapirat, Siriwat ^e   Pattanachaiwit, Supanit ^a   Fletcher, James L K ^a   Chomchey, Nitiya ^a   Kroon, Eugene D ^a   Ubolyam, Sasiwimol ^f   Michael, Nelson L ^d,g   Robb, Merlin L ^c,d   Phanuphak, Praphan ^a   Kim, Jerome H ^h   Phanuphak, Nittaya ^a   Ananworanich, Jintanat ^a,c,d   Teeratakulpisarn, Nipat ⁱ   Colby, Donn ⁱ   Sutthichom, Duanghathai ⁱ   Rattanamanee, Somprartthana ⁱ   Prueksakaew, Peeriya ⁱ   Eamyoung, Pacharin ⁱ   Puttamaswin, Suwanna ⁱ   Tipsuk, Somporn ⁱ   Karnsomlap, Putthachard ⁱ   Trichavaroj, Rapee ^j   Nuntapinit, Bessara ^j   Panjapornsuk, Pornchanok ^j   Tongchanakarn, Bhubate ^j   Kobchit, Wanwarang ^j   Ngauy, Viseth ^j   O'Connell, Robert ^j   Tantibul, Nantana ^j   Savadsuk, Hathairat ^j   Assawadarachai, Vatcharain ^j   Tovanabutra, Sodsai ^k   more..

^a THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^b Thai Red Cross AIDS Research Centre ^*  (United States)

^c Henry M Jackson Foundation for the Advancement of Military Medicine   (United States)

^d US Military HIV Research Program   (United States)

^e Armed Forces Research Institute of Medical Sciences San Francisco   (United States)

^f THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^g WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^h International Vaccine Institute   (South Korea)

ⁱ TRCARC   (United States)

^j AFRIMS   (United States)

^k US Militar HIV Research Program   (United States)

more..

Author keywords

Acute HIV infection; Bangkok; HIV 1; Immunoassay; Seroreversion

Indexed keywords

ANTIRETROVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOGLOBULIN G; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ANTIBODY DETECTION; ARTICLE; BISEXUALITY; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; FEMALE; HETEROSEXUAL FEMALE; HETEROSEXUAL MALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MEN WHO HAVE SEX WITH MEN; PRIORITY JOURNAL; SEROLOGY; WESTERN BLOTTING; ACUTE DISEASE; ADOLESCENT; BLOOD; COHORT ANALYSIS; DIAGNOSTIC TEST; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MALE HOMOSEXUALITY; MIDDLE AGED; PROSPECTIVE STUDY; SEXUAL AND GENDER MINORITY; THAILAND; YOUNG ADULT;

ACUTE DISEASE; ADOLESCENT; ADULT; ANTI-HIV AGENTS; COHORT STUDIES; DIAGNOSTIC TESTS, ROUTINE; FEMALE; HIV ANTIBODIES; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HOMOSEXUALITY, MALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RNA, VIRAL; SEXUAL AND GENDER MINORITIES; THAILAND; YOUNG ADULT;

EID: 84982142923     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw365     Document Type: Article

References (40)

1. INSIGHT START Study Group; Lundgren JD, Babiker AG, Gordin F, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 2015; 373:795-807
2. World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva, Switzerland: WHO, 2015
3. Tabernilla A, Poveda E. The START trial: definitive evidence to treat all HIVpositive persons regardless of CD4 counts. AIDS Rev 2015; 17:187
4. Hong FF, Mellors JW. Changes in HIV reservoirs during long-term antiretroviral therapy. Curr Opin HIV AIDS 2015; 10:43-8
5. Branson BM. The future of HIV testing. J Acquir Immune Defic Syndr 2010; 55 (suppl 2):S102-5
6. Branson BM. HIV testing updates and challenges: when regulatory caution and public health imperatives collide. Curr HIV/AIDS Rep 2015; 12:117-26
7. Masciotra S, Smith AJ, Youngpairoj AS, et al. Evaluation of the CDC proposed laboratory HIV testing algorithm among men who have sex with men (MSM) from five US metropolitan statistical areas using specimens collected in 2011. J Clin Virol 2013; 58(suppl 1):e8-12
8. Centers for Disease Control and Prevention and Association of Public Health Laboratories. Laboratory testing for the diagnosis of HIV infections: updated recommendations, 2014. Available at: https://stacks.cdc.gov/view/cdc/23447. Accessed 12 December 2014
9. Dugast AS, Stamatatos L, Tonelli A, et al. Independent evolution of Fc-and Fab-mediated HIV-1-specific antiviral antibody activity following acute infection. Eur J Immunol 2014; 44:2925-37
10. McMichael AJ, Borrow P, Tomaras GD, Goonetilleke N, Haynes BF. The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol 2010; 10:11-23
11. Tomaras GD, Yates NL, Liu P, et al. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulinM(IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol 2008; 82:12449-63
12. Yates NL, Lucas JT, Nolen TL, et al. Multiple HIV-1-specific IgG3 responses decline during acute HIV-1: implications for detection of incident HIV infection. AIDS 2011; 25:2089-97
13. Yates NL, Stacey AR, Nolen TL, et al. HIV-1 gp41 envelope IgA is frequently elicited after transmission but has an initial short response half-life. Mucosal Immunol 2013; 6:692-703
14. Liu P, Overman RG, Yates NL, et al. Dynamic antibody specificities and virion concentrations in circulating immune complexes in acute to chronic HIV-1 infection. J Virol 2011; 85:11196-207
15. Ananworanich J, Fletcher JL, Pinyakorn S, et al. A novel acute HIV infection staging system based on 4th generation immunoassay. Retrovirology 2013; 10:56
16. Fiebig EW, Wright DJ, Rawal BD, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 2003; 17:1871-9
17. Amor A, Toro C, Jimenez V, Simon A, Ramos B, Soriano V. Seroreversion of HIV antibodies in patients with prolonged suppression of viraemia under HAART. AIDS 2006; 20:1460-2
18. Hare CB, Pappalardo BL, Busch MP, et al. Seroreversion in subjects receiving antiretroviral therapy during acute/early HIV infection. Clin Infect Dis 2006; 42:700-8
19. Kassanjee R, Pilcher CD, Keating SM, et al. Independent assessment of candidate HIV incidence assays on specimens in the CEPHIA repository. AIDS 2014; 28:2439-49
20. Killian MS, Norris PJ, Rawal BD, et al. The effects of early antiretroviral therapy and its discontinuation on the HIV-specific antibody response. AIDS Res Hum Retroviruses 2006; 22:640-7
21. Markowitz M, Vesanen M, Tenner-Racz K, et al. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses. J Infect Dis 1999; 179:527-37
22. O'Connell RJ, Merritt TM, Malia JA, et al. Performance of the OraQuick rapid antibody test for diagnosis of human immunodeficiency virus type 1 infection in patients with various levels of exposure to highly active antiretroviral therapy. J Clin Microbiol 2003; 41:2153-5
23. Ananworanich J, Puthanakit T, Suntarattiwong P, et al. Reduced markers of HIV persistence and restricted HIV-specific immune responses after early antiretroviral therapy in children. AIDS 2014; 28:1015-20
24. Asang C, Laws HJ, Adams O, et al. HIV-1 seroreversion in HIV-1-infected children: do genetic determinants play a role? AIDS 2014; 28:543-7
25. Eberle J, Notheis G, Blattmann C, et al. Seroreversion in vertically HIV-1-infected children treated early and efficiently: rule or exception? AIDS 2010; 24:2760-1
26. Jurriaans S, Sankatsing SU, Prins JM, et al. HIV-1 seroreversion in an HIV-1-seropositive patient treated during acute infection with highly active antiretroviral therapy and mycophenolate mofetil. AIDS 2004; 18:1607-8
27. Kassutto S, Johnston MN, Rosenberg ES. Incomplete HIV type 1 antibody evolution and seroreversion in acutely infected individuals treated with early antiretroviral therapy. Clin Infect Dis 2005; 40:868-73
28. Ananworanich J, Schuetz A, Vandergeeten C, et al. Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. PLoS One 2012; 7:e33948
29. De Souza MS, Phanuphak N, Pinyakorn S, et al. Impact of nucleic acid testing relative to antigen/antibody combination immunoassay on the detection of acute HIV infection. AIDS 2015; 29:793-800
30. Schuetz A, Deleage C, Sereti I, et al. Initiation of ART during early acute HIV infection preserves mucosal Th17 function and reverses HIV-related immune activation. PLoS Pathog 2014; 10:e1004543
31. Ly TD, Ebel A, Faucher V, Fihman V, Laperche S. Could the new HIV combined p24 antigen and antibody assays replace p24 antigen specific assays? J Virol Methods 2007; 143:86-94
32. Arroyo MA, Phanuphak N, Krasaesub S, et al. HIV type 1 molecular epidemiology among high-risk clients attending the Thai Red Cross Anonymous Clinic in Bangkok, Thailand. AIDS Res Hum Retroviruses 2010; 26:5-12
33. Pinter A, Honnen WJ, Tilley SA, et al. Oligomeric structure of gp41, the transmembrane protein of human immunodeficiency virus type 1. J Virol 1989; 63:2674-9
34. Branson BM, Stekler JD. Detection of acute HIV infection: we can't close the window. J Infect Dis 2012; 205:521-4
35. Masciotra S, McDougal JS, Feldman J, Sprinkle P, Wesolowski L, Owen SM. Evaluation of an alternative HIV diagnostic algorithm using specimens from seroconversion panels and persons with established HIV infections. J Clin Virol 2011; 52 (suppl 1):S17-22
36. Payne H, Mkhize N, Otwombe K, et al. Reactivity of routine HIV antibody tests in children who initiated antiretroviral therapy in early infancy as part of the Children with HIV Early Antiretroviral Therapy (CHER) trial: a retrospective analysis. Lancet Infect Dis 2015; 15:803-9
37. Piwowar-Manning E, Fogel JM, Richardson P, et al. Performance of the fourthgeneration Bio-Rad GS HIV Combo Ag/Ab enzyme immunoassay for diagnosis of HIV infection in Southern Africa. J Clin Virol 2015; 62:75-9
38. Ly TD, Laperche S, Brennan C, et al. Evaluation of the sensitivity and specificity of six HIV combined p24 antigen and antibody assays. J VirolMethods 2004; 122:185-94
39. Owen SM, Yang C, Spira T, et al. Alternative algorithms for human immunodeficiency virus infection diagnosis using tests that are licensed in the United States. J Clin Microbiol 2008; 46:1588-95
40. Moon HW, Huh HJ, Oh GY, et al. Evaluation of the Bio-Rad Geenius HIV 1/2 confirmation assay as an alternative to Western blot in the Korean population: a multi-center study. PLoS One 2015; 10:e0139169